60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare 60 Degrees Pharmaceuticals to similar companies based on the strength of its profitability, dividends, earnings, institutional ownership, risk, analyst recommendations and valuation.
Risk and Volatility
60 Degrees Pharmaceuticals has a beta of 2.47, meaning that its share price is 147% more volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals’ competitors have a beta of -3.71, meaning that their average share price is 471% less volatile than the S&P 500.
Profitability
This table compares 60 Degrees Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 60 Degrees Pharmaceuticals | -650.21% | N/A | -136.81% |
| 60 Degrees Pharmaceuticals Competitors | -2,380.38% | -217.94% | -15.54% |
Earnings & Valuation
This table compares 60 Degrees Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| 60 Degrees Pharmaceuticals | $1.41 million | -$7.36 million | -0.12 |
| 60 Degrees Pharmaceuticals Competitors | $3.56 billion | $3.19 billion | 555.10 |
60 Degrees Pharmaceuticals’ competitors have higher revenue and earnings than 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for 60 Degrees Pharmaceuticals and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 60 Degrees Pharmaceuticals | 1 | 2 | 1 | 0 | 2.00 |
| 60 Degrees Pharmaceuticals Competitors | 7798 | 13888 | 25778 | 1037 | 2.41 |
60 Degrees Pharmaceuticals presently has a consensus target price of $13.85, indicating a potential upside of 2,228.12%. As a group, “Pharmaceuticals” companies have a potential upside of 25.60%. Given 60 Degrees Pharmaceuticals’ higher probable upside, equities analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than its competitors.
Insider & Institutional Ownership
8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
60 Degrees Pharmaceuticals competitors beat 60 Degrees Pharmaceuticals on 9 of the 13 factors compared.
60 Degrees Pharmaceuticals Company Profile
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
